Isentress Tablet, containing Raltegravir, is an antiretroviral medicine used in the treatment of HIV-1 infection. It belongs to the class of integrase inhibitors and works by preventing the virus from multiplying in the body. When taken with other antiretroviral medicines, Isentress helps lower the viral load, supports immune system recovery, and reduces the risk of HIV-related complications. For detailed medical insights, you can refer to trusted resources like Mayo Clinic, Drugs.com, and FDA.

Key Benefits & Uses

• Helps manage HIV-1 infection effectively.

• Works as part of combination therapy to reduce viral load.

• Improves immune system strength and overall health.

• Reduces risk of opportunistic infections.

• Safe and well-tolerated in adults and children (as prescribed).
  Learn more about its medical significance at PubMed and WHO.

How to Use

• Take Isentress Tablet exactly as prescribed by your healthcare provider.

• It can be taken with or without food.

• Swallow the tablet whole with water, do not crush or chew.

• Consistency is key: take it at the same time every day for best results.
  Additional dosing details are available at WebMD and Healthline.

Important Safety Information

• Do not stop taking Isentress without consulting your doctor, as this may increase the risk of resistance.

• Inform your doctor about other medicines or supplements you are taking.

• Use with caution if you have liver or muscle-related conditions.

• Pregnant or breastfeeding women should consult their physician before use.

Common Side Effects

Some patients may experience mild side effects, including:

• Headache

• Insomnia

• Nausea or diarrhea

• Muscle pain or weakness
  If symptoms persist or worsen, seek medical guidance. More information is available at FDA and Mayo Clinic.

Why Choose Isentress?

Isentress (Raltegravir) is a trusted HIV medication recommended worldwide due to its proven efficacy, minimal drug interactions, and suitability for both adults and children. Supported by strong clinical evidence on PubMed and WHO, it remains a preferred option for long-term HIV management.